Cargando…
Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study
SIMPLE SUMMARY: Advanced thymic carcinoma (ATC) is rare. Owing to its rarity, there is limited information on the prognostic factors, and the optimal serum tumor markers are also unknown. We conducted a multi-institutional retrospective study of patients with ATC. In this study, we collected data on...
Autores principales: | Mimori, Tomoyasu, Shukuya, Takehito, Ko, Ryo, Okuma, Yusuke, Koizumi, Tomonobu, Imai, Hisao, Takiguchi, Yuichi, Miyauchi, Eisaku, Kagamu, Hiroshi, Sugiyama, Tomohide, Azuma, Keisuke, Namba, Yukiko, Yamasaki, Masahiro, Tanaka, Hisashi, Takashima, Yuta, Soda, Sayo, Ishimoto, Osamu, Koyama, Nobuyuki, Kobayashi, Kunihiko, Takahashi, Kazuhisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773938/ https://www.ncbi.nlm.nih.gov/pubmed/35053494 http://dx.doi.org/10.3390/cancers14020331 |
Ejemplares similares
-
Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
por: Miyauchi, Eisaku, et al.
Publicado: (2022) -
Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma
por: Kaira, Kyoichi, et al.
Publicado: (2021) -
CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma
por: Kanamori, Koichiro, et al.
Publicado: (2023) -
Salvage Chemotherapy in Patients with Previously Treated Thymic Carcinoma
por: Kaira, Kyoichi, et al.
Publicado: (2021) -
A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress)
por: Kaira, Kyoichi, et al.
Publicado: (2020)